HCPs, regarding bispecific antibodies for multiple myeloma, which of the following AE mitigation strategies do you use most routinely in your practice? #MultipleMyeloma #myeloma #mmsm #MedEd

🎥 CRS typically occurs following the first or second step-up dose of bispecific antibody therapy. Where available, prophylactic tocilizumab may be considered to help mitigate CRS. Watch the full video here: bit.ly/4qSXKMe #MultipleMyeloma #myeloma #mmsm #MedEd @mvmateos Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.

How do dose modifications impact belantamab mafodotin safety and efficacy in patients with RRMM? Read our latest article here: bit.ly/4AR6ze2 #mmsm #myeloma #MedEd #MedNews

CONGRESS | #IMS26 | PRESENTATION Evangelos Terpos, National and Kapodistrian University of Athens, presented results from the multicenter, open-label, phase II EAE116 trial evaluating Isa-VCd induction followed by Isa-R maintenance in patients with NDMM and severe renal impairment (N = 51). Among evaluable patients (n = 50), 88% achieved a hematologic ORR, with a median time to first response of 1 month. Among renal-response-evaluable patients (n = 49), 75.5% achieved ≥MRR and 38.8% achieved ≥PR. The median time to best renal response was 2.4 months and the median time to ≥MR was 1.1 months. MRD negativity was achieved in 72% of evaluable patients (n = 25). Dialysis independence was achieved in >50% of patients who were dialysis-dependent at baseline. TEAEs occurred in 88.2% of patients (Grade ≥3, 41.2%; Grade 5, 21.6%). Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @uoaofficial

CONGRESS | #IMS26 | PRESENTATION Meletios Dimopoulos, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, presented long-term results of the randomized phase III DREAMM-8 trial evaluating BPd (n = 155) vs PVd (n = 147) in patients with RRMM who had received ≥1 prior line of therapy. At a median follow-up of 35.8 months, patients receiving BPd were >4 times more likely to achieve ≥ CR + MRD negativity (27.7% vs 6.1%) and >5 times more likely to achieve MRD negativity sustained ≥12 months (15.5% vs 2.7%) than those receiving PVd. Sustained MRD negativity was associated with durable PFS and PFS2 in both treatment groups. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @thanosdimop

CONGRESS | #IMS26 | PRESENTATION Giada Bianchi, Dana-Farber Cancer Institute, presented phase I results from an open-label phase I/II study evaluating safety, tolerability, and efficacy of elranatamab in patients with relapsed AL amyloidosis who had received ≥1 prior LOT (N = 11). CRS occurred in 73% of patients (Grade 1, 46%; Grade 2, 27%; no Grade ≥3); no neurotoxicity events were reported. Infections were frequent and recurrent, the most common being upper respiratory tract infection (45.4%). At a median follow-up of 12.4 months, 100% of patients achieved a hematological response (CR, 90.9%; VGPF, 9.1%). All patients achieved deep suppression of iFLC within one cycle of therapy. A phase II study is currently enrolling patients. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @DanaFarber

CONGRESS | #IMS26 | PRESENTATION Alexis Talbot, Hôpital Saint-Louis, presented the results of a prospective phase II trial, evaluating Dara-VRd induction followed by tandem ASCT, Dara-VRd consolidation and lenalidomide maintenance in patients with newly diagnosed primary PCL (N = 29). Following induction, 79% of patients achieved ≥VGPR, including 27% who achieved a CR/sCR. Among evaluable patients after the second ASCT (n = 22), 95% achieved ≥VGPR including 63% who achieved a CR/sCR. MRD negativity was achieved by 24% of patients after induction and by 52% after the second ASCT. At a median follow up of 20 months, the median PFS was NR, with an estimated PFS of 76% at 18 months and 57% at 24 months. The most common AE during induction was neuropathy, occurring in 20 patients. No death related to either first or second ASCT occurred. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @HopSaintLouis

CONGRESS | #IMS26 | PRESENTATION Jieqiong Zhou, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, presented results from the prospective phase II AL-003 trial evaluating low-dose CM336, a BCMA × CD3 bispecific antibody, as frontline therapy in patients with newly diagnosed systemic AL amyloidosis (N = 21). Hematologic response was achieved by 100% of patients (CR, 71.4%; VGPR, 28.6%); median time to CR was 49 days and median time to ≥PR was 10 days. Cardiac response was achieved in 71.4% of evaluable patients (n = 14; CR, 7.1%; VGPR, 14.3%; PR, 50%), with a median time to response of 38.5 days. Renal response was achieved in 100% of evaluable patients (n = 16; CR, 37.5%; VGPR, 31.2%; PR, 31.2%) with a median time to response of 41.5 days. The most common TEAEs were lymphopenia (76.2%; Grade 3/4, 61.9%), hypogammaglobulinemia (71.4%; no Grade 3/4) and leukopenia (61.9%; Grade 3/4, 19.0%). Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress

CONGRESS | #IMS26 | PRESENTATION Paula Rodríguez-Otero, Clínica Universidad de Navarra, presents findings from the phase II GEM-TECTAL trial, investigating efficacy and safety of teclistamab-daratumumab (Tec-D) intensification following daratumumab-bortezomib-lenalidomide-dexamethasone (DVRd) induction in patients with ND-HRMM (N = 30). After Tec-D intensification, MRD(–) CR rate was 73.3%. All patients achieved ≥VGPR and 83.3% achieved CR/sCR after 6 cycles. Of 25 evaluable patients, 22 achieving CR were MRD(–). In the safety population (n = 28), TEAEs occurred in 96.4% of patients during Tec-D intensification, with infections occurring in 78.6%. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @paurotero @ClinicaNavarra

CONGRESS | #IMS26 | PRESENTATION Benjamin Puliafito, Mass General Brigham Cancer Institute, presents findings from the phase II EPIC trial, investigating eltranatamab (Elra) as a fixed-duration consolidation after idecabtagene vicleucel (IC) in patients with RRMM (N = 25). At median FU of 9.8 months after Elra administration, median PFS had not been reached. Of 23 evaluable patients, CR/sCR was achieved in 83% of patients. All patients with <CR post-IC (n = 14) had deepened IMWG response. All 5 MRD(+) patients at screening became MRD(–) upon completion of Elra. CRS occurred in 44% of patients, no ICANS occurred. Grade 3/4 non-hematologic and non-infectious AEs occurred in 32% of patients. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @MassGenBrigham

CONGRESS | #IMS26 | PRESENTATION Sven Neubert, University Hospital of Würzburg, presents real-world findings for idecabtagene vicleucel (IC) and ciltacabtagene autoleucel (CC) in patients with CNS-MM (N = 25). Median PFS and OS were 6.3 vs 13.9 months for IC and CC, respectively. No significant difference was observed between IC and CC for PFS (6.3 vs 13.9 months; p = 0.95) and OS (13.1 vs 13.9 months; p = 0.88). CNS disease control at CAR-T infusion numerically improved PFS compared with no prior CNS control (10.5 vs 6.3 months). Progressive disease was observed in 8/15 IC patients and 4/10 CC patients. Grade ≥3 CRS occurred in two IC patients and grade 1 ICANS occurred in four patients, two each for IC and CC. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress

CONGRESS | #IMS26 | PRESENTATION Jin Lu, Peking University People’s Hospital, presents real-world efficacy and safety data for equecabtagene autoleucel in patients with RRMM (N = 281). Of 267 evaluable patients, ORR, CR, and ≥VGPR were 95.9%, 77.2%, and 86.9%, respectively. At median FU of 10.97 months, median PFS and OS were not reached. Outcomes were consistent across higher-risk subgroups, including patients >70 years of age and anti-CD38–exposed patients. Any grade CRS was 88.2% and any grade ICANS was 6.8%. High-risk patients (113/150; 75.3%), as defined by CAR-HT, had lower 12-month PFS and higher toxicity compared with low-risk patients (24.7%), despite similar ORR. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress

CONGRESS | #IMS26 | PRESENTATION Cesar Rodriguez, Icahn School of Medicine at Mount Sinai, presents findings from Arm E of the phase Ib Kilimanjaro trial, investigating etentamig plus pomalidomide and dexamethasone in RRMM after 1–3 prior lines of therapy (N = 58). At median FU of 11 months, ORR and ≥VGPR were 91% and 79%, respectively, across doses. With 40 mg etentamig, ORR was 88% at median FU of 12 months. MRD(−) status was achieved in 100% of evaluable ≥CR patients treated with 40 mg etentamig (n = 11), and 96% across all doses (n = 23). Median PFS and DoR were not reached. Neutropenia was the most common Grade 3–4 TEAE (57%). Grade 3–4 infections and any grade CRS events occurred in 28% and 24% of patients, respectively. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @IcahnMountSinai

CONGRESS | #IMS26 | PRESENTATION Doris Hansen, Moffitt Cancer Center, presents initial findings from a phase I trial investigating BMS-986453 in patients with RRMM (N = 58). Patients were administered 25, 75, 150 or 300 million (M) CAR T-cells. At median FU of 12 months, ORR was 83% for all doses. In patients who were BCMA/GPRC5D-naïve and treated with 75 or 15 million CAR T cells (n=16), ORR was 83%, and 100% achieved ≥VGPR and were MRD(−) at 10⁻⁵ threshold. Dose-limiting toxicities occurred in 19% of patients. Grade 3/4 TEAEs were reported in 98% of patients; neutropenia (88%) and thrombocytopenia (48%) were the most common. Follow our live feed for more updates: bit.ly/4cWKNew Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence. #MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @MoffittNews